Market Research Report
Investigation Report on China's Meropenem Market 2021-2025
|Published by||China Research and Intelligence||Product code||1002606|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Meropenem Market 2021-2025|
|Published: April 23, 2021||Content info: 50 Pages||
Meropenem is an antibiotic that is used to treat a variety of bacterial infections, including meningitis, pneumonia and so on. Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial Chemical Industries (ICI). It was launched in the Chinese market in 1999. Currently, besides Sumitomo Dainippon Pharma, the other main manufacturers in the Chinese market are Shenzhen Haibin Pharmaceutical, CSPC Ouyi Pharmaceutical Group, Hanhui Pharmaceuticals, and Haikou Pharmaceutical Factory.
According to CRI's market research, the sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, the sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year. The main reason is that the COVID-19 epidemic has impacted the hospitals' overall operation. The CAGR of sales value of Meropenem in China is 2% in 2016 to 2020.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Meropenem will have a recovery growth from 2021 to 2025. In addition, the strict limits on the usage of antibiotic drugs and the emergence of drug resistance have driven the demand for more effective antibacterial drugs. Therefore, Meropenem, as a new generation of antibacterial drugs, has the potential to expand its sales in the future.